Recruiting
Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection
The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.
ClinicalTrials.gov IDNCT06970288
PhaseNot Applicable
Enrollment85
SponsorAin Shams University
Age30 Years
SexFEMALE
Conditions studied
Breast Carcinoma
About this study
The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.
Primary outcomes
- To evaluate the capability of detecting suspicious breast lesions using non-contrast enhanced MRI protocol featuring ultra-high B-value (20 months)
Eligibility information
Inclusion Criteria:
* • Women with suspicious breast mass (BIRADS 4a)
* High risk women (Positive family history)
* Women with suspicious axillary lymph nodes by Ultrasound
* Women with dense breasts coming for MRI imaging.
Exclusion Criteria:
* • Contraindications to MRI
* Pacemaker, cochlear implant, claustrophobia, ocular implants
* Contraindications to contrast administration:
* Elevated kidney functions
* Women who haven't undergone reliable Mammogram \& Ultrasound
* Women with prior treatment or intervention (e.g. biopsy)
* Patients' refusal.
Study locations
- Ain Shams University, Cairo, Abbasia Egypt
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.